Peripheral DES
This article was originally published in The Gray Sheet
Executive Summary
Edwards will focus development of peripheral drug-eluting stents on "vessels where we think we can excel," CEO Michael Mussallem reports during Feb. 3 earnings call. "For example, we think we can do quite well in the SFA," or superficial femoral artery, he says. Edwards has several internal peripheral DES programs, including a research alliance with San Diego-based Happy Valley Medical, developer of the anti-proliferative drug Ceracor (C6-ceramide). HVM is also the "sister company" of stent developer Reva Medical. Meanwhile, Boston Scientific and J&J/Cordis will soon turn their attention to renal drug-eluting stents, Mussallem predicts. "The first target [for] the coronary players...will be the renals. That's a natural target for interventional cardiologists and a natural place for them to be effective"...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.